NASDAQ:VVOS Vivos Therapeutics (VVOS) Stock Price, News & Analysis → Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (From Colonial Metals) (Ad) Free VVOS Stock Alerts $2.59 +0.13 (+5.28%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$2.48▼$2.6150-Day Range$2.46▼$5.8152-Week Range$2.37▼$48.79Volume67,574 shsAverage Volume386,376 shsMarket Capitalization$7.72 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Vivos Therapeutics alerts: Email Address Ad Prosper Trading AcademyThese AI trades triggered this morning (545% return)If you think a market crash is possible in 2024, I don't know why you're not using this yet. Click Here To Get Your Free Copy About Vivos Therapeutics Stock (NASDAQ:VVOS)Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado.Read More VVOS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VVOS Stock News HeadlinesApril 11, 2024 | proactiveinvestors.comVivos Therapeutics expects increased adoption of oral medical devices following Medicare reimbursement approvalApril 9, 2024 | finance.yahoo.comVivos Therapeutics receives approval for Medicare reimbursement for flagship Oral Medical DevicesApril 28, 2024 | True Market Insiders (Ad)Exposed: 10 CENT Crypto to Explode April 20th?The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…April 9, 2024 | markets.businessinsider.comVivos Gets Approval To Facilitate Full Medicare Reimbursement For CARE Sleep Apnea Oral DevicesApril 9, 2024 | msn.comWhat's Going On With Vivos Therapeutics Stock?April 9, 2024 | msn.comMedicare to reimburse for Vivos CARE sleep apnea devicesApril 9, 2024 | proactiveinvestors.comVivos Therapeutics CARE oral medical devices approved for Medicare reimbursementApril 9, 2024 | investorplace.comWhy Is Vivos Therapeutics (VVOS) Stock Up 16% Today?April 28, 2024 | True Market Insiders (Ad)Exposed: 10 CENT Crypto to Explode April 20th?The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…April 9, 2024 | msn.comVivos Therapeutics files to sell 1.73M shares of common stock for holdersApril 9, 2024 | finance.yahoo.comVivos Therapeutics’ Flagship CARE Oral Medical Devices Receive Full Approval for Medicare ReimbursementApril 9, 2024 | globenewswire.comVivos Therapeutics' Flagship CARE Oral Medical Devices Receive Full Approval for Medicare ReimbursementApril 1, 2024 | proactiveinvestors.comVivos Therapeutics highlights path to cash flow positivity after FDA clearanceMarch 31, 2024 | finance.yahoo.comVivos Therapeutics Full Year 2023 Earnings: Misses ExpectationsMarch 30, 2024 | seekingalpha.comVivos Therapeutics, Inc. (VVOS) Q4 2023 Earnings Call TranscriptMarch 29, 2024 | marketwatch.comVivos Therapeutics Shares Fall After Wider-Than-Expected 4Q LossMarch 28, 2024 | globenewswire.comVivos Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Operational UpdateMarch 28, 2024 | globenewswire.comVivos Therapeutics Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Conference CallFebruary 22, 2024 | benzinga.comVivos Therapeutics Stock (NASDAQ:VVOS), Short Interest ReportFebruary 22, 2024 | benzinga.comVivos Therapeutics Stock (NASDAQ:VVOS) Insider TradesFebruary 18, 2024 | investing.comVivos Therapeutics secures $4 million through warrant exerciseFebruary 15, 2024 | finance.yahoo.comVivos Therapeutics Announces Exercise of Warrants for Approximately $4.0 Million Aggregate Gross ProceedsFebruary 15, 2024 | proactiveinvestors.comVivos Therapeutics sees gross proceeds of $4M from exercise of warrantFebruary 12, 2024 | finance.yahoo.comVivos Therapeutics CEO Kirk Huntsman Discusses FDA Approval and Market DisruptionsFebruary 6, 2024 | finanznachrichten.deVivos Therapeutics, Inc: Vivos Therapeutics Highlights Significant Favorable Market Developments Creating Exciting New Growth OpportunitiesFebruary 6, 2024 | finance.yahoo.comVivos Therapeutics Highlights Significant Favorable Market Developments Creating Exciting New Growth OpportunitiesJanuary 8, 2024 | finance.yahoo.comVivos Therapeutics Sees Positive Preliminary Metrics Following Unprecedented FDA 510(k) Clearance of the Company’s Proprietary Oral Medical Devices to Treat Severe OSASee More Headlines Receive VVOS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vivos Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/28/2024Today4/27/2024Next Earnings (Estimated)6/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical Devices Sub-IndustryN/A Current SymbolNASDAQ:VVOS CUSIPN/A CIK1716166 Webwww.vivoslife.com Phone866-908-4867FaxN/AEmployees114Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($11.05) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-13,580,000.00 Net Margins-98.42% Pretax Margin-98.42% Return on Equity-665.17% Return on Assets-122.48% Debt Debt-to-Equity RatioN/A Current Ratio0.34 Quick Ratio0.34 Sales & Book Value Annual Sales$13.80 million Price / Sales0.56 Cash FlowN/A Price / Cash FlowN/A Book Value$0.22 per share Price / Book11.77Miscellaneous Outstanding Shares2,980,000Free Float2,696,000Market Cap$7.72 million OptionableOptionable Beta7.94 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. R. Kirk Huntsman (Age 66)Co-Founder, Chairman of the Board & CEO Comp: $482.16kMr. Bradford K. Amman (Age 62)CFO, Treasurer & Secretary Comp: $335.53kMr. Todd HuntsmanCo-Founder & Senior VP of Product and TechnologyMs. RaeAnn ByrnesCo-Founder and Senior VP of Events & Clinical Advisory ServicesMs. Susan McCulloughCo-Founder & Executive VP of OperationsMs. Julie GannonSenior VP of Strategic Sales & Marketing and Investor Relations OfficerMr. Nicholas M. DeGennaroSenior Vice President of Medical Integration DivisionMs. Ruth HembreeSenior Vice President of Practice ServicesMs. Stephanie HuebnerSenior Vice President of Dental Service IntegrationMr. John BallardSenior Vice President of TechnologyMore ExecutivesKey CompetitorsPlus TherapeuticsNASDAQ:PSTVVapothermNYSE:VAPOIntelligent Bio SolutionsNASDAQ:INBSAvingerNASDAQ:AVGRNeuroMetrixNASDAQ:NUROView All CompetitorsInsiders & InstitutionsArmistice Capital LLCBought 57,000 shares on 2/13/2024Ownership: 4.286%Ronald Kirk HuntsmanBought 560 shares on 6/20/2023Total: $7,420.00 ($13.25/share)Ronald Kirk HuntsmanBought 600 shares on 6/16/2023Total: $8,100.00 ($13.50/share)Ronald Kirk HuntsmanBought 400 shares on 6/14/2023Total: $4,900.00 ($12.25/share)View All Insider TransactionsView All Institutional Transactions VVOS Stock Analysis - Frequently Asked Questions How have VVOS shares performed in 2024? Vivos Therapeutics' stock was trading at $12.44 at the beginning of the year. Since then, VVOS stock has decreased by 79.2% and is now trading at $2.59. View the best growth stocks for 2024 here. Are investors shorting Vivos Therapeutics? Vivos Therapeutics saw a increase in short interest during the month of April. As of April 15th, there was short interest totaling 191,100 shares, an increase of 921.9% from the March 31st total of 18,700 shares. Based on an average trading volume of 210,400 shares, the days-to-cover ratio is currently 0.9 days. Currently, 7.6% of the shares of the company are short sold. View Vivos Therapeutics' Short Interest. When is Vivos Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, June 13th 2024. View our VVOS earnings forecast. How were Vivos Therapeutics' earnings last quarter? Vivos Therapeutics, Inc. (NASDAQ:VVOS) issued its quarterly earnings data on Thursday, March, 28th. The company reported ($3.05) earnings per share for the quarter. The company earned $3.25 million during the quarter. Vivos Therapeutics had a negative net margin of 98.42% and a negative trailing twelve-month return on equity of 665.17%. When did Vivos Therapeutics' stock split? Vivos Therapeutics's stock reverse split on Friday, October 27th 2023. The 1-25 reverse split was announced on Friday, October 27th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, October 27th 2023. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. When did Vivos Therapeutics IPO? Vivos Therapeutics (VVOS) raised $20 million in an IPO on Friday, December 11th 2020. The company issued 3,300,000 shares at a price of $5.00-$7.00 per share. Roth Capital Partners acted as the underwriter for the IPO and Craig-Hallum Capital Group and National Securities Corporation were co-managers. How do I buy shares of Vivos Therapeutics? Shares of VVOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:VVOS) was last updated on 4/28/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressThe A.I. story nobody is telling you (Read ASAP)TradeSmithProtect Your Bank Account Before It’s Too LateWeiss RatingsWhy Big Pharma is Investing Billions in This BiotechBehind the MarketsJeff Bezos Just Humiliated Elon MuskInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vivos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
